Mediterranean Journal of Hematology and Infectious Diseases

Acquired haemophilia A is a serious and potentially fatal bleeding disorder. Diagnosis is difficult and maybe delayed due to its rarity. The high mortality rate and the complex nature of treatment necessitate patient management at a and resources are available. Prompt diagnosis is crucial and early initiation of therapy could be life saving. Management includes initial control of bleeding followed by an approach to eradicate the coagulation factor inhibitor. In this paper we describe our local experience with acquired haemophilia A, which resulted in the successful control of major bleeding at presentation and eradication of inhibitors. Introduction. Acquired haemophilia A (AHA) is a rare but often fatal bleeding disorder. typically lack previous or family history of bleeding. Presentation is acute with sudden onset of bleeding, spontaneously or following a hemostatic challenge. In contrast to congenital haemophilia, which is characterized by hemarthrosis, bleedin with AHA commonly affects soft tissues. associated with a high mortality rate of 9 untreated. Prompt diagnosis and management are important for a favorable outcome. In this paper we describe our local experience with idiopathic AHA demonstrating the heterogeneity of clinical presentation, prognostic and therapeutic aspects of this disorder. Definition. AHA is caused by the development of www.mjhid.org ISSN 2035-3006 . Hematology Department, Kingabdulaziz [email protected] at no competing interests exist. 2, 4(1): e2012021, DOI: 10.4084/MJHID.2012.021 ), which permits unrestricted use, distribution, and reproduction in